Lantern Pharma (NASDAQ: LTRN) has announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), delivering a real-time, web-based molecular intelligence engine that enables researchers to generate comprehensive developability profiles for small molecules from a single SMILES input. The enhanced platform leverages Lantern’s RADR AI technology to provide rapid, high-dimensional analysis across physicochemical properties, drug-likeness, structural architecture and topological mapping, with benchmark-validated performance and accessibility designed to streamline drug discovery workflows and broaden access to advanced computational tools.
This development is significant because it represents a major step in democratizing advanced AI-driven drug discovery capabilities. By allowing researchers to input a single SMILES notation—a standard chemical notation system—and receive a full developability profile, the predictBBB LQM removes barriers to accessing sophisticated computational tools. This could accelerate early-stage drug discovery for academic labs, biotech startups, and pharmaceutical companies that may lack in-house AI expertise.
The platform’s ability to analyze multiple dimensions of molecular properties simultaneously means researchers can quickly identify promising drug candidates and flag potential issues before committing significant resources to development. This could reduce the time and cost associated with bringing new therapies to patients, particularly in oncology where Lantern Pharma focuses its pipeline.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR platform to transform the development of cancer therapies. The company’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary.
Additionally, Lantern’s withZeta.ai platform, a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. Lantern operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more information on the predictBBB expansion, visit the full press release at https://ibn.fm/XqWld. To stay updated on Lantern Pharma news, see the company’s newsroom at https://ibn.fm/LTRN.
